Ronald B Postuma,Alex Iranzo,Michele Hu,Birgit Högl,Bradley F Boeve,Raffaele Manni,Wolfgang H Oertel,Isabelle Arnulf,Luigi Ferini-Strambi,Monica Puligheddu,Elena Antelmi,Valerie Cochen De Cock,Dario Arnaldi,Brit Mollenhauer,Aleksandar Videnovic,Karel Sonka,Ki-Young Jung,Dieter Kunz,Yves Dauvilliers,Federica Provini,Simon J Lewis,Jitka Buskova,Milena Pavlova,Anna Heidbreder,Jacques Y Montplaisir,Joan Santamaria,Thomas R Barber,Ambra Stefani,Erik K St.Louis,Michele Terzaghi,Annette Janzen,Smandra Leu-Semenescu,Guiseppe Plazzi,Flavio Nobili,Friederike Sixel-Doering,Petr Dusek,Frederik Bes,Pietro Cortelli,Kaylena Ehgoetz Martens,Jean-Francois Gagnon,Carles Gaig,Marco Zucconi,Claudia Trenkwalder,Ziv Gan-Or,Christine Lo,Michal Rolinski,Philip Mahlknecht,Evi Holzknecht,Angel R Boeve,Luke N Teigen,Gianpaolo Toscano,Geert Mayer,Silvia Morbelli,Benjamin Dawson,Amelie Pelletier

Abstract:Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.

Baseline characteristics of the North American prodromal Synucleinopathy cohort

Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder

Clinical characteristics and phenoconversion in isolated REM sleep behavior disorder: a prospective single-center study in Korea, compared with Montreal cohort

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

0697 DIAGNOSIS DELAY and FAILED RECOGNITION of RBD: FROM “FITS to PARKINSON’S DISEASE”

Phenoconversion in Women and Men With Isolated REM Sleep Behavior Disorder: A Retrospective Cohort Study

IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter Study

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Developing disease-modifying interventions in idiopathic REM sleep behavior disorder and early synucleinopathy

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder

Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study

Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder

Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects

Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy

The fate of patients with REM sleep behavior disorder and mild cognitive impairment

1012 Concordance and Test-Retest Consistency of Sleep Biomarker Based Phenotyping of Neurodegenerative Disorders